Micrus Endovascular Receives FDA Approval for Intracranial Stent Clinical Trial (Centre Daily Times)
Micrus Endovascular Corporation (Nasdaq:MEND) today announced that the Vitesse Intracranial Stent Study for Ischemic Therapy (VISSIT) clinical trial application has been conditionally approved by the U.S. Food and Drug Administration (FDA). The Pharos(TM) Vitesse(TM) intracranial stent is Micrus Endovascular's second balloon-expandable stent for the treatment of intracranial ischemic stenosis ...

FDA Panel Rejects Black Box Warning On Epilepsy Drugs (Medical News Today)
A panel of experts that advises the US Food and Drug Administration (FDA) voted last week to reject the Agency's proposal to make manufacturers of 11 epilepsy drugs put the strongest level of warning label on their products (the Black Box warning).